

# Obesity hypoventilation Syndrome

Babak Mokhlesi, M.D., M.Sc.

Professor of Medicine

Director, Sleep Disorders Center

Section of Pulmonary and Critical Care Medicine

University of Chicago

# Conflict of Interest Disclosures for Speakers

1. I do not have any relationships with any entities **producing, marketing, re-selling, or distributing** health care goods or services consumed by, or used on, patients, OR

2. I have the following relationships with entities **producing, marketing, re-selling, or distributing** health care goods or services consumed by, or used on, patients.

Type of Potential Conflict	Details of Potential Conflict
Grant/Research Support	NIH/NHLBI and Philips/Respironics
Consultant	
Speakers' Bureaus	Zephyr Medical Technologies
Financial support	
Other	

3. The material presented in this lecture has no relationship with any of these potential conflicts, OR

4. This talk presents material that is related to one or more of these potential conflicts, and the following objective references are provided as support for this lecture:


- 1.
- 2.
- 3.


# Objectives

---

- ◆ Review the definition and epidemiology of OHS
- ◆ Understand the clinical presentation and diagnosis and when to suspect OHS
- ◆ Recognize the high morbidity and mortality associated with undiagnosed and untreated OHS
  - Postoperative risk of OHS
- ◆ Discuss treatment strategies

# An example of a patient with OHS





# Definition and epidemiology

# Definition of OHS

---

## Required conditions

---


- |                                     |  |
|-------------------------------------|--|
| Obesity                             | <ul style="list-style-type: none"><li>• Body mass index <math>\geq 30</math> kg/m<sup>2</sup></li></ul>  |
| Chronic Hypoventilation             | <ul style="list-style-type: none"><li>• Awake daytime hypercapnia (PaCO<sub>2</sub> <math>\geq 45</math> mm Hg)</li></ul>  |
| Sleep-disordered breathing          | <ul style="list-style-type: none"><li>• OSA (AHI <math>\geq 5</math>) present in 90% of cases</li><li>• Sleep hypoventilation (AHI <math>&lt; 5</math>) present in 10%</li></ul>   |
| Exclude other causes of hypercapnia | <ul style="list-style-type: none"><li>• Significant obstructive airways disease</li><li>• Significant interstitial lung disease</li><li>• Severe chest wall disorders (e.g., kyphoscoliosis)</li><li>• Severe hypothyroidism</li><li>• Neuromuscular disease</li></ul> |
-

# Obesity Hypoventilation Syndrome

Diagnosis of Exclusion!




# Highest Increases in Clinically Severe Obesity, U.S. 1986-2005



# Prevalence of OHS in obese patients being evaluated for OSA


Author, Country	Year	Patients (No.)	Male (%)	Age (yrs)	BMI (kg/m <sup>2</sup> )	AHI	OHS (%)
Leech, US <sup>x</sup>	1987	111	68%	47	NR	58	37%
Resta, Italy <sup>x</sup>	2000	219	64%	50	40	45	17%
Verin, France <sup>x</sup>	2001	218	92%	55	34	51	10%
Akashiba, Japan	2002	143	100%	48	30	55	38%
Laaban, France	2005	1141	83%	56	34	55	11%
Mokhlesi, US <sup>x</sup>	2007	522	56%	48	44	59	24%
Kawata, Japan <sup>x</sup>	2007	1227	89%	50	29	42	14%
Banerjee, Australia <sup>†</sup>	2007	74	54%	43	59	62	31%
Macavei, UK <sup>x</sup>	2013	344	64%	52	39	25	21%
Aggregate or mean		<b>3999</b>	<b>74%</b>	<b>50</b>	<b>38</b>	<b>50</b>	<b>17%</b>

# Prevalence of Obesity Hypoventilation Syndrome in patients with OSA



# Estimated prevalence of OHS in the general population

---



# Diagnosis and Presentation

# Clinical features of OHS from 16 studies and a total of 757 patients

---

<b>Variables</b>	<b>Mean (range)</b>
Age, year	52 (42-61)
Men, %	60 (49-90)
Body mass index, kg/m <sup>2</sup>	44 (35-56)
Neck circumference, cm	46.5 (45-47)
pH	7.38 (7.34-7.40)
PaCO <sub>2</sub> , mm Hg	53 (47-61)
PaO <sub>2</sub> , mm Hg	56 (46-74)
Serum bicarbonate, mEq/L	32 (31-33)
Hemoglobin, g/dL	15
MRC dyspnea class 3 and 4, %	69
Epworth sleepiness scale	14 (12-16)

# PSG and PFT features of OHS from 16 studies and a total of 757 patients

---

<b>Variables</b>	<b>Mean (range)</b>
Apnea-hypopnea index	66 (20-100)
SpO <sub>2</sub> nadir during sleep, %	65 (59-76)
Percent time SpO <sub>2</sub> < 90%, %	50 (46-56)
FVC, % of predicted	68 (57-102)
FEV <sub>1</sub> , % of predicted	64 (53-92)
FEV <sub>1</sub> /FVC	77 (74-88)

# Two Patterns of Presentation

---

- ◆ Acute on chronic respiratory failure
  - 8% of all admissions to ICU had a diagnosis consistent with OHS
  - 75% were misdiagnosed as COPD with no evidence of obstruction on PFT

Marik PE, Desai H. *J Intensive Care Med* 2012; 28:124

- ◆ As part of routine evaluation of OSA
- ◆ Frequently missed and diagnosed at late stage by pulmonologists or sleep specialists

Quint et al, *Thorax* 2007




# When to suspect OHS

---

- ◆ Severely obese (BMI  $\geq$  40)
- ◆ Elevated venous bicarbonate levels from recent basic metabolic panels
- ◆ Room air hypoxemia by finger pulse oximetry
- ◆ Significant and persistent hypoxemia during PSG
- ◆ Spirometry/PFT with mild restrictive defect due to body habitus

# Bicarbonate as a screening tool



Mokhlesi B et al. *Sleep Breath* 2007; 11:117

Macavei VM, et al. *JCSM* 2013; 9:879-84

A one unit increase in serum HCO<sub>3</sub> was associated with a 14% increase in the probability of having OHS

BaHammam AS. *Saudi Med J* 2015; 36:181-189

# Does the current definition need revisiting?

---


- ◆ The current definition is based on a single one-time measurement of PaCO<sub>2</sub>
- ◆ Calculated arterial or measured venous bicarbonate is a longer term guide to 24-h ventilation
- ◆ Proposed new definition:
  - Obesity
  - PaCO<sub>2</sub> ≥45 mm Hg OR an arterial base excess >3 mmol/L OR a standard HCO<sub>3</sub> >27 mmol/L
  - absence of another cause for a metabolic alkalosis

## Is a raised bicarbonate level without hypercapnia part of the spectrum of OHS?

	Eucapnic normal BE n=33	Eucapnic Elevated BE n=22	Hypercapnic Elevated BE n=16	P value
Age	53.6	48.7	53.7	0.09
BMI	45.2 (9.1)	46.5 (7.9)	51.6 (11.7)	0.056
<b>Base Excess, mEq/L</b>	<b>0.12 (1.38)</b>	<b>3.01 (0.98)</b>	<b>4.78 (2.10)</b>	<b>&lt;0.001</b>
HCO <sub>3</sub> , mEq/L	24.4 (1.18)	27.0 (0.87)	28.5 (2.11)	<0.001
pH	7.41	7.44	7.41	<0.001
PaCO <sub>2</sub> , mm Hg	38.6	40.6	49.6	<0.001
SpO <sub>2</sub>	96	96.3	92.4	0.007
VE, L/min	8.05	8.33	7.54	0.47
<b>VE hypercapnic test, L/min</b>	<b>14.6</b>	<b>11.96</b>	<b>11.76</b>	<b>0.035</b>


# Pathophysiology of respiratory failure in OHS

# Pathophysiology of respiratory failure




# Pathophysiology of respiratory failure

---



# How does sleep hypoventilation lead to wake hypoventilation





# Morbidity and Mortality

# Clinical Implications of OHS


---

- ◆ Compared to simple eucapnic OSA, patients with OHS have:
  - Lower quality of life
  - Greater healthcare expenses
  - Higher risk of pulmonary hypertension
  - Higher risk of death attributed to:
    - ❖ severe obesity
    - ❖ severe OSA
    - ❖ chronic respiratory failure

Berg G. Chest 2001; 120:377-83  
Hida W. Sleep Breath. 2003; 7:1

OHS in hospitalized patients

# Outcome of patients admitted to medicine wards found to have OHS



**31% of obese patients admitted to the wards were found to have undiagnosed OHS (BMI  $45 \pm 9$ )  
NO HOSPITAL DEATHS but more ICU transfers and intubations**


- ◆ Mortality at 18 months was 23% vs. 9% (HR=4.0; 95% CI: 1.5 to 10.4)
- ◆ Adjusted for age, BMI, electrolytes, renal and thyroid function

# Causes of acute on chronic hypercapnic respiratory failure in OHS

---

- ◆ Prospective study over 13 years in Spain
- ◆ 173 OHS patients with acute exacerbation
- ◆ BMI 42, age 74
- ◆ Only 9% of OHS were on home NIV but 39% on oxygen
- ◆ Causes of exacerbation:
  - Respiratory infection: 68%
  - Cardiac: 13%
  - Depressant drugs: 5%
  - Trauma: 3%
  - Surgery: 3%

# Outcomes in OHS after acute hypercapnic respiratory failure treated with NIV



- ◆ OHS n=173, BMI 42, age 74
- ◆ COPD n=543, BMI 30, age 71
- ◆ Only 9% of OHS were on home NIV but 39% on oxygen
- ◆ 4% in each group required ET-T intubation
- ◆ OHS had lower ICU and hospital mortality (6% vs. 18%)
- ◆ Adjusted survival was not significantly different (p=0.11)
- ◆ At one year 45% were on CPAP and 10% on NIV

# Long-term survival compared to OSA

---

- ◆ Retrospective study of 110 OHS vs 220 matched OSA patients
  - Similar age, sex, AHI, Epworth
  - PAP adherence ~ 6 h/night in both groups
  - Mean NIV 18/8 cm H<sub>2</sub>O in OHS, mean CPAP 9 cm H<sub>2</sub>O in OSA
  - Mean follow-up time of 7±4 years
- ◆ Five year mortality rates:
  - OHS: 15.5%
  - OSA: 4.5%
  - Risk of mortality: OR 2 (95% CI: 1.11-3.60)
  - Risk of CV event: OR 1.86 (95% CI: 1.14-3.04)
  - Strongest predictor of mortality was adherence to NIV < 4 hours

Treatment



# Therapeutic options

---

- ◆ Positive airway pressure therapy
- ◆ Surgery
  - Tracheostomy
  - Bariatric surgery
- ◆ Pharmacological therapy
  - Medroxyprogesterone
  - Acetazolamide
  - Oxygen

# PAP Therapeutic options

---

- ◆ Positive airway pressure therapy
  - CPAP
  - Bi-level PAP (spontaneous mode or S/T)
  - Volume-targeted pressure support
    - ❖ AVAPS (Respironics)
    - ❖ iVAPS (ResMed)

# CPAP or bilevel PAP S mode in OHS

---

- ◆ CPAP titration failure rate can be as high as 43% in patients with OHS due to persistent hypoxemia


Banerjee D, et al. *Chest* 2007; 131:1678

- ◆ In an RCT, 36 patients were randomized to CPAP (n=18) vs. bi-level PAP in spontaneous mode (n=18) for 3 months
  - CPAP failures were excluded
  - Change in PaCO<sub>2</sub> was 5.8 mm Hg with CPAP and 6.9 in bilevel PAP S mode

Piper AJ et al. *Thorax* 2008; 63:395

# Volume-Targeted Pressure Support

- ◆ Automatically adjusts IPAP to guarantee a target tidal volume



Murphy PB et al. Thorax 2012;67(8):727-34

Masa JF et al. AJRCCM 2015; 192: 86

# AVAPS vs. bilevel PAP/ST in OHS

---


- ◆ RCT of 50 OHS patients to bilevel PAP/ST vs. AVAPS
  - 34% enrolled during an acute-on-chronic respiratory failure
- ◆ At three months there was no group differences in:
  - PaCO<sub>2</sub> and PaO<sub>2</sub>
  - Epworth and QOL
  - Decrease in BMI
  - Improvement in FVC

# No differences in ventilator parameters


Parameters	AVAPS (n=25)	Bi-level PAP/ST (n=25)
Delivered IPAP, cm H <sub>2</sub> O	22±5	23±4
Set EPAP, cm H <sub>2</sub> O	9±1	10±2
Leak, L/min	53±13	53±19
Patient triggered breaths, %	43±27	45±27
Mean adherence, h:min	4:11±2:53	5:08±2:22
Delta PaCO <sub>2</sub> , mm Hg	- 4.5±7.5	- 4.5±8.2

AVAPS set in pressure control mode, tidal volume of 8-10 ml/kg IBW

# Efficacy of Different Treatment Alternatives for Obesity Hypoventilation Syndrome: Pickwick Study




# Efficacy of Different Treatment Alternatives for Obesity Hypoventilation Syndrome: Pickwick Study





# NIV in patients with OHS without severe OSA



# NIV in patients with OHS without severe OSA

- ◆ NIV was more effective in improving PSG parameters, ESS and QoL

	Baseline, mean (SD)/median (IQR)		Intra-group differences, mean (95% CI)		p Value of inter-group differences§	
	NIV	Control	NIV	Control	Unadjusted	Adjusted
PaCO <sub>2</sub> , mm Hg	49 (4.0)	49 (3.5)	-6 (-7.7 to -4.2)‡	-2.8 (-4.3 to -1.3)‡	0.006	0.019
Serum bicarbonate, mmol/L	30 (4.1)	29 (3.8)	-3.4 (-4.5 to -2.3)‡	-1 (-1.7 to -0.2)*	0.000	0.004
pH	7.400 (0.040)	7.400 (0.030)	0.005 (-0.005 to 0.157)	0.031 (-0.008 to 0.147)	NS	-
PaO <sub>2</sub> , mm Hg	64 (10)	67 (10)	4.6 (0.5 to 8.8)*	1.4 (-2.6 to 5.5)	NS	-
FEV <sub>1</sub> , %	72 (16)	80 (20)	1.8 (-2.7 to 6.4)	1.9 (-1.2 to 5.1)	NS	-
FVC, %	75 (21)	82 (20)	4.7 (-4.2 to 14)	2.9 (-0.5 to 6.3)	NS	-
6-MWD, m	309 (105)	349 (105)	29 (-16 to 74)	-7.2 (-25 to 11)	NS	-
Systolic BP, mm Hg	136 (18)	136 (15)	-4.2 (-11 to 2.5)	-4.3 (-10 to 1.7)	NS	-
Diastolic BP, mm Hg	80 (16)	80 (18)	0.5 (-5.3 to 6.2)	-1.2 (-5.4 to 2.9)	NS	-

# Impact of PAP Adherence on hypercapnia/hypoxemia in OHS

Subgroup	N (%)	Change in PaCO <sub>2</sub>	Change in PaO <sub>2</sub>
		<i>Mean ± SD</i>	
<b>Adherence with therapy</b>			
Average PAP use > 4.5 h/day	34 (45%)	<b>8±5</b>	<b>9±11</b>
Average PAP use < 4.5 h/day	41 (55%)	2±4	2±9

# Non PAP treatment modalities

---

- ◆ Oxygen: no role as single therapy
  - At high concentrations it can increase  $\text{PaCO}_2$  because of reduction in minute ventilation
    - ❖ Wijesinghe M, et al. *Chest* 2011; 139:1018
    - ❖ Mokhlesi B, et al. *Chest*. 2011 ;139:975
- ◆ Recent study revealed that 20 minutes of  $\text{FiO}_2$  at 50% increased  $\text{PavCO}_2$  from 53 mm Hg to 58 mm Hg with a drop in tidal volume by 89 ml.
  - ❖ Hollier CA et al. *Thorax*. 2014; 69(4):346-53

# Need for oxygen during PAP titration

---

- ◆ During CPAP titration 43% required supplemental oxygen (average CPAP pressures of 14 cm H<sub>2</sub>O).

Banerjee D, *Chest*. 2007; 131:1678

Mokhlesi B, *J Clin Sleep Med*. 2006; 2:57

- ◆ Other studies of similar patients undergoing aggressive NIV titration (IPAP of ~ 13 cm H<sub>2</sub>O above an average EPAP of 10), or volume targeted pressure support only 12%-23% required oxygen supplementation

Murphy PB et al. *Thorax* 2012;67:727


Masa JF et al. *AJRCCM* 2015; 192:86

# The effect of supplemental oxygen in OHS in the Pickwick study

---

- ◆ Post-hoc analysis of a previous RCT
- ◆ 302 sequentially screened OHS patients who were randomly assigned to NIV, CPAP, or lifestyle modification.
  - 78 out of 302 (26%) were prescribed home oxygen therapy
- ◆ Oxygen therapy (1-2 L/min) was not associated with an increase in worsening ABG or hospital resource utilization in any of the groups at two months.
- ◆ Long-term studies are necessary.

# Tracheostomy



- ◆ Retrospective study
- ◆ 13 patients with OSA plus OHS
- ◆ Tracheostomy improved but did not fully resolve SDB in patients with OSA plus OHS
  - NREM AHI 64 to 31
  - REM AHI 46 to 39
  - 7/13 had AHI > 20
  - Persistent SDB due orifice obstruction b/o chin or neck adiposity or central sleep apnea
- ◆ Hypercapnia resolved in most patients


# Impact of Bariatric Surgery on Respiratory Insufficiency

---

- ◆ 29 patients with OHS or OSA+OHS
- ◆ Mean weight loss of  $50 \pm 29$  kg ( $110 \pm 65$  pounds)
- ◆  $\text{PaO}_2$  increased from  $53 \pm 9$  to  $68 \pm 11$  mm Hg
- ◆  $\text{PaCO}_2$  decreased from  $51 \pm 7$  to  $41 \pm 4$  mm Hg
- ◆ Hb decreased from 16.9 to 14.9 g/dl
- ◆ Significant improvements in ERV, FRC, FVC



# Postoperative complications in patients with unrecognized OHS: A retrospective study




# Adjusted postoperative complications in patients with unrecognized OHS


Postoperative Outcome	Hypercapnic OSA (n = 194)	OSA (n = 325)	OR (95% CI)	P Value
Respiratory failure	39 (21)	8 (2)	10.9 (3.7-32.3)	< .0001
Heart failure	15 (8)	0	5.4 (1.9-15.7)	.002
Prolonged intubation	24 (13)	12 (4)	3.1 (0.6-15.3)	.2
Reintubation	12 (6)	5 (2)	1.7 (0.2-13.4)	.6
Tracheostomy	4 (2)	3 (1)	3.8 (1.7-8.6)	.002
ICU transfer	41 (21)	19 (6)	10.9 (3.7-32.3)	< .0001
Death at 30 d	2 (1)	0	... <sup>a</sup>	...
Death at 1 y	10 (5)	2 (0.6)	0.9 (0.1-7.5)	.9

Variables	Hypercapnic OSA (n = 194)	OSA (n = 325)	$\beta \pm SE$	P
ICU length of stay, d			$0.86 \pm 0.32$	.009
Median (IQR)	0 (0-0)	0 (0-0)		
Mean $\pm$ SD	0.12 (0.93)	1.04 (3.8)		
Hospital length of stay, d			$2.94 \pm 0.87$	.0008
Median (IQR)	5 (3-9)	0 (0-4)		
Mean $\pm$ SD	7.3 (8.2)	2.8 (5.1)		


# Postoperative complications in patients with OSA: hypercapnia may be more relevant than AHI!



AHI 45  
3% ODI 2  
T90 0 min  
Arousal index 50




AHI 45  
3% ODI 43  
T90 9 min  
Arousal index 36



AHI 45  
3% ODI 47  
T90 77 min  
Arousal index 43

# One possible preoperative approach to OHS



# Research questions

---

- ◆ How to best screen preoperative patients for unrecognized OHS
- ◆ How to approach patients with OHS who are nonadherent to PAP therapy
- ◆ How safe is postop supplemental oxygen
- ◆ Best monitoring strategies for patients with hypercapnia
  - Oxygenation
  - Ventilation
- ◆ Avoiding management pitfalls:
  - Over diuresis
  - Excessive oxygen supplementation

# Conclusions

---

- ◆ OHS is prevalent in patients with severe obesity and OSA
- ◆ It is frequently unrecognized and undertreated
- ◆ Untreated OHS significantly increases the risk of morbidity and mortality
- ◆ Comprehensive treatment strategies should focus on:
  - Nocturnal resolution of sleep disordered breathing
  - Weight loss
  - Increasing physical activity